MVA-BN-RSV vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00437 | 0.00322 | 0.00592 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0037 | 0.00265 | 0.00516 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.000668 | -0.00119 | 0.00254 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.18 | 0.75 | 1.86 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.749 | 1.86 | log | ClinicalTrials.gov | |
| Number needed to harm, for one more death from any cause on MVA-BN-RSV than on Placebo | 1,500 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | MVA-BN-RSV | Single administration of MVA-BN-RSV vaccine with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL (intramuscular injection).~Group assignment based on actual treatment, i.e. participants treated with MVA-BN-RSV (including 8747 Single Enroller participants randomized to MVA-BN-RSV and treated with MVA-BN-RSV + 1 Single Enroller participant randomized to Placebo and treated with MVA-BN-RSV + 179 Multiple Enroller participants randomized to MVA-BN-RSV (first randomization) and treated with MVA-BN-RSV only + 230 Multiple Enroller participants randomized to MVA-BN-RSV (first randomization) and treated with at least one dose of Placebo + 232 Multiple Enroller participants randomized to Placebo (first randomization) and treated with at least one dose of MVA-BN-RSV). | 41 | 9,389 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Single administration of Tris Buffered Saline (TBS) (intramuscular injection; 0.5mL).~Group assignment based on actual treatment, i.e. participants treated with Placebo (including 8770 Single Enroller participants randomized to Placebo and treated with Placebo + 4 Single Enroller participants randomized to MVA-BN-RSV and treated with Placebo + 185 Multiple Enroller participants randomized to Placebo (first randomization) and treated with Placebo only (at least 2 doses and up to 4 doses) + 232 Multiple Enroller participants randomized to Placebo (first randomization) and treated with at least one dose of MVA-BN-RSV). | 34 | 9,191 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | From vaccination through study termination, up to 16 months | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | MVA-BN-RSV Vaccine Trial | ClinicalTrials.gov |
| NCT number | NCT05238025 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Respiratory Syncytial Virus Infections | ClinicalTrials.gov |
| Interventions | MVA-BN-RSV vaccine, Tris Buffered Saline (TBS) | ClinicalTrials.gov |
| Lead sponsor | Bavarian Nordic | ClinicalTrials.gov |
| Results first posted | 2024-10-31 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT05238025?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.